Biopharmaceuticals major Biocon said on Monday the board of its subsidiary Biocon Biologics has approved a primary equity investment by True North which will invest Rs 536.25 crore to pick 2.44 per cent minority stake in the biosimilars business. ...
Pharmaceuticals major Biocon Ltd on Monday said that its subsidiary Biocon Biologics India has approved the acquisition of 2.44 per cent stake in it by private equity firm True North with an investment of Rs 536.25 crore. ...
Indian's insurance regulator has approved divestment of 51 per cent stake of Max India in Max Bupa Health Insurance Company to private equity firm True North. ...